ATE232393T1 - Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung - Google Patents

Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung

Info

Publication number: ATE232393T1
Authority: AT; Austria
Prior art keywords: substances; wound healing; production; medicinal products; oxytocin
Prior art date: 1997-03-27

Application number

AT98912862T

Other languages

English (en)

Inventor

Thomas Lundeberg

Moberg Kerstin Uvnaes

Original Assignee

Entretech Medical Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-27

Filing date

1998-03-26

Publication date

2003-02-15

1998-03-26 Application filed by Entretech Medical Ab filed Critical Entretech Medical Ab

2003-02-15 Application granted granted Critical

2003-02-15 Publication of ATE232393T1 publication Critical patent/ATE232393T1/de

Links

XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title abstract 3
101800000989 Oxytocin Proteins 0.000 title abstract 3
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 title abstract 3
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title abstract 3
229960001723 oxytocin Drugs 0.000 title abstract 3
239000000126 substance Substances 0.000 title abstract 2
230000029663 wound healing Effects 0.000 title abstract 2
229940126601 medicinal product Drugs 0.000 title 1
206010052428 Wound Diseases 0.000 abstract 2
208000027418 Wounds and injury Diseases 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
230000001684 chronic effect Effects 0.000 abstract 1
238000009109 curative therapy Methods 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002035 prolonged effect Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

AT98912862T 1997-03-27 1998-03-26 Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung ATE232393T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9701162A SE9701162D0 (sv)	1997-03-27	1997-03-27	New use II
PCT/SE1998/000554 WO1998043661A1 (en)	1997-03-27	1998-03-26	Use of substances having oxytocin activity for preparation of medicaments for wound healing

Publications (1)

Publication Number	Publication Date
ATE232393T1 true ATE232393T1 (de)	2003-02-15

Family

ID=20406369

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98912862T ATE232393T1 (de)	1997-03-27	1998-03-26	Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung

Country Status (10)

Country	Link
US (1)	US6262021B1 (de)
EP (1)	EP1003542B1 (de)
JP (1)	JP2001519786A (de)
CN (1)	CN1251530A (de)
AT (1)	ATE232393T1 (de)
AU (1)	AU749479B2 (de)
DE (1)	DE69811371T2 (de)
ES (1)	ES2194308T3 (de)
SE (1)	SE9701162D0 (de)
WO (1)	WO1998043661A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080004224A1 (en) *	1994-05-04	2008-01-03	Hlavka Joseph J	Dermatological uses of tri-, tetra-, penta-, and polypeptides
SE9701184D0 (sv) *	1997-04-01	1997-04-01	Karolinska Innovations Ab	Substanser för att åstadkomma preferens och skapa acceptans
SE9803272D0 (sv) *	1998-09-25	1998-09-25	Kerstin Uvnaes Moberg	A drug for cell regeneration
SE0001440D0 (sv) *	2000-04-18	2000-04-18	Entretech Medical Ab	A drug against climacteric disorders
SE0100684D0 (sv) *	2001-02-28	2001-02-28	Kerstin Uvnaes Moberg	New subject-matter
KR100441167B1 (ko) *	2001-12-27	2004-07-21	씨제이 주식회사	마이크로에멀젼 예비 농축액 조성물
ATE410170T1 (de) *	2003-03-27	2008-10-15	Pantarhei Bioscience Bv	Verwendung von estrogenen zur behandlung von männerunfruchtbarkeit
JO2937B1 (en) *	2004-08-11	2016-03-15	فيرينغ.بي.في	Tight muscles of the peptide vascular tensioner receptor
JP4747364B2 (ja) *	2005-04-04	2011-08-17	独立行政法人産業技術総合研究所	紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤
US7660413B2 (en) *	2005-04-08	2010-02-09	Shahram Partovi	Secure digital couriering system and method
JP5276982B2 (ja)	2005-08-26	2013-08-28	ボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティ	オキシトシンの投与による頭痛の処置のための方法
KR101194586B1 (ko) *	2006-02-10	2012-10-25	훼링 비.브이.	신규 화합물
US20080004223A1 (en) *	2006-05-17	2008-01-03	Hlavka Joseph J	Dermatological uses of the tripeptide melanocyte stimulating inhibitory factor (mif)
WO2009037586A2 (en) *	2007-08-14	2009-03-26	Ferring B.V.	Use of peptidic vasopressin receptor agonists
JP2010538979A (ja) *	2007-09-11	2010-12-16	モンドバイオテックラボラトリーズアクチエンゲゼルシャフト	Ｓ．Ｐｎｅｕｍｏｎｉａｅの感染等を処置するための治療剤としての、ＲＧＤＳＰＡＳＳＫＰ、および随意的なアンギオテンシンＩＩの使用
JP2010539002A (ja) *	2007-09-11	2010-12-16	モンドバイオテックラボラトリーズアクチエンゲゼルシャフト	ウロジラチンの治療剤としての使用
WO2009033820A2 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
KR20100056508A (ko) *	2007-09-11	2010-05-27	몬도바이오테크 래보래토리즈 아게	폐렴 연쇄상 구균 감염의 치료를 위한 ｂｆｇｆ１－２４ 및 임의의 （ａｒｇ８）바소프레신의 용도
WO2009033665A2 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent
CA2701420C (en) *	2007-10-29	2016-02-09	Helix Biomedix Inc.	Protective skin care tetrapeptides
WO2011140608A1 (en) *	2010-05-14	2011-11-17	Keating Charlotte L	Neuropsychopharmacological treatment regimes for treating psychological disorders
EP2582791B8 (de) *	2010-06-18	2018-05-23	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	Neogenese von haarfollikeln
WO2012016229A2 (en) *	2010-07-30	2012-02-02	The Regents Of The University Of California	Oxytocin treatment to improve memory and modify blood glucose
SE536091C2 (sv)	2011-04-14	2013-04-30	Pep Tonic Medical Ab	Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
US9757388B2 (en)	2011-05-13	2017-09-12	Acerus Pharmaceuticals Srl	Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en)	2011-05-13	2013-02-21	Trimel Pharmaceuticals Corporation	Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
AR086400A1 (es)	2011-05-13	2013-12-11	Trimel Pharmaceuticals Corp	Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
DE102011118016A1 (de) *	2011-10-26	2013-05-02	Henkel Ag & Co. Kgaa	Kosmetische Mittel enthaltend Oxytocin und Riechstoffe
US9387183B2 (en)	2011-12-28	2016-07-12	Kuwait University	Method of treating diabetes-related impaired wound healing
US11744838B2 (en)	2013-03-15	2023-09-05	Acerus Biopharma Inc.	Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
EP2991692B1 (de)	2013-05-03	2019-08-21	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	Hautersatzstoffe und verfahren zur neubildung von haarfollikeln
AU2015270723A1 (en) *	2014-06-03	2016-11-17	F. Hoffmann-La Roche Ag	Peptides as oxytocin agonists
SG11201705591PA (en)	2015-01-07	2017-08-30	Trigemina Inc	Magnesium-containing oxytocin formulations and methods of use
JP7093559B2 (ja)	2016-04-12	2022-06-30	トライジェミナ，インコーポレイテッド	マグネシウム含有オキシトシン製剤および使用の方法
CN107456570A (zh) *	2017-07-31	2017-12-12	温州医科大学附属第二医院、温州医科大学附属育英儿童医院	催产素在促进缺血超长随意皮瓣存活中的作用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3274060A (en) *	1962-05-23	1966-09-20	Armour Pharma	Treatment of multiple sclerosis with oxytocin
NL129421C (de) *	1963-08-30	1900-01-01
EP0300036A4 (de) *	1987-01-30	1989-06-14	Biomed Res Consultants Ltd	Auf vasopressin basierte arzneimittelzubereitungen.
US5175144A (en) *	1988-11-29	1992-12-29	The Johns Hopkins University	Method of retarding the progression of chronic renal failure
SE9701161D0 (sv) *	1997-03-27	1997-03-27	Karolinska Innovations Ab	New use I

1997
- 1997-03-27 SE SE9701162A patent/SE9701162D0/xx unknown
1998
- 1998-03-26 ES ES98912862T patent/ES2194308T3/es not_active Expired - Lifetime
- 1998-03-26 WO PCT/SE1998/000554 patent/WO1998043661A1/en not_active Ceased
- 1998-03-26 AT AT98912862T patent/ATE232393T1/de active
- 1998-03-26 CN CN98803766A patent/CN1251530A/zh active Pending
- 1998-03-26 AU AU67550/98A patent/AU749479B2/en not_active Ceased
- 1998-03-26 DE DE69811371T patent/DE69811371T2/de not_active Expired - Lifetime
- 1998-03-26 JP JP54154798A patent/JP2001519786A/ja not_active Ceased
- 1998-03-26 EP EP98912862A patent/EP1003542B1/de not_active Expired - Lifetime
- 1998-03-26 US US09/381,799 patent/US6262021B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU6755098A (en)	1998-10-22
SE9701162D0 (sv)	1997-03-27
ES2194308T3 (es)	2003-11-16
WO1998043661A1 (en)	1998-10-08
JP2001519786A (ja)	2001-10-23
DE69811371D1 (de)	2003-03-20
EP1003542B1 (de)	2003-02-12
US6262021B1 (en)	2001-07-17
DE69811371T2 (de)	2003-12-18
CN1251530A (zh)	2000-04-26
AU749479B2 (en)	2002-06-27
EP1003542A1 (de)	2000-05-31

Legal Events

Date

Code

Title

Description

2003-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1003542

Country of ref document: EP

Publication	Publication Date	Title
ATE232393T1 (de)	2003-02-15	Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung
DE59911740D1 (de)	2005-04-14	Topisch anwendbare mittel gegen nagelpilzerkrankungen
ATE274916T1 (de)	2004-09-15	Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
SE9401406D0 (sv)	1994-04-25	Pharmaceutical products for curing tumourous diseases and process for preparing same
DE60004974D1 (de)	2003-10-09	Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
ATE415962T1 (de)	2008-12-15	Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE69902234D1 (de)	2002-08-29	Matrixprotein enthaltende zusammensetzungen zur wundheilung
ATE243196T1 (de)	2003-07-15	Piperidine und pyrrolidine
ES2181165T3 (es)	2003-02-16	Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.
HUP9602498A2 (hu)	1998-04-28	Antimikrobiális hatású gyógyászati készítmények
DE68910973D1 (de)	1994-01-05	Arzneimittelzusammensetzung, enthaltend deoxyribonukleoside für heilung von wunden.
ATE55695T1 (de)	1990-09-15	Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
ATE275966T1 (de)	2004-10-15	Activin stimulator enthaltende pharmazeutische zusammensetzung
DE69910202D1 (de)	2003-09-11	EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
DE60015560D1 (de)	2004-12-09	Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz
ES2191449T3 (es)	2003-09-01	Derivados de ciclopentabenzofurano y su uso.
ATE252383T1 (de)	2003-11-15	Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
MX9202366A (es)	1992-11-01	Nuevas 2-amino-5-ciano-1,4-di hidro piridinas y procedimiento para su fabricacion.
DE59704194D1 (de)	2001-09-06	Verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren zur herstellung von arzneimitteln
DE68905657D1 (de)	1993-05-06	Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE69531554D1 (de)	2003-09-25	Verwendung von inosittriphosphat zur herstellung von arzneimitteln
ATE234613T1 (de)	2003-04-15	Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE59805246D1 (de)	2002-09-26	Tissue-faktor zur beeinflussung von gefässbildung
ATE137968T1 (de)	1996-06-15	Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
ATE326954T1 (de)	2006-06-15	Transdermales therapeutisches system zur verabreichung von calciumantagonisten